Bamco Inc. NY Trims Holdings in AstraZeneca PLC (NASDAQ:AZN)

Bamco Inc. NY decreased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 11.4% during the third quarter, HoldingsChannel.com reports. The firm owned 133,244 shares of the company’s stock after selling 17,207 shares during the period. Bamco Inc. NY’s holdings in AstraZeneca were worth $10,381,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in AstraZeneca during the second quarter worth about $26,000. Capital Performance Advisors LLP bought a new position in AstraZeneca in the 3rd quarter worth about $28,000. Hobbs Group Advisors LLC purchased a new stake in shares of AstraZeneca in the 2nd quarter valued at about $35,000. Finally, Versant Capital Management Inc boosted its position in shares of AstraZeneca by 1,614.8% during the 2nd quarter. Versant Capital Management Inc now owns 463 shares of the company’s stock valued at $36,000 after acquiring an additional 436 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.9 %

Shares of AZN opened at $67.04 on Tuesday. The firm has a fifty day simple moving average of $72.27 and a two-hundred day simple moving average of $77.44. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The stock has a market capitalization of $207.86 billion, a P/E ratio of 32.08, a PEG ratio of 1.24 and a beta of 0.45. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the firm earned $0.87 earnings per share. On average, research analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on AZN. TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.